CN112972753A - Sustained-release embolism microsphere for treating bronchiectasis hemoptysis caused by chronic inflammation - Google Patents
Sustained-release embolism microsphere for treating bronchiectasis hemoptysis caused by chronic inflammation Download PDFInfo
- Publication number
- CN112972753A CN112972753A CN201911216938.6A CN201911216938A CN112972753A CN 112972753 A CN112972753 A CN 112972753A CN 201911216938 A CN201911216938 A CN 201911216938A CN 112972753 A CN112972753 A CN 112972753A
- Authority
- CN
- China
- Prior art keywords
- release
- water
- sustained
- microsphere
- glucocorticoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 58
- 238000013268 sustained release Methods 0.000 title claims abstract description 40
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 40
- 208000005189 Embolism Diseases 0.000 title claims abstract description 32
- 208000000616 Hemoptysis Diseases 0.000 title claims abstract description 19
- 201000009267 bronchiectasis Diseases 0.000 title claims abstract description 16
- 208000037976 chronic inflammation Diseases 0.000 title claims abstract description 8
- 230000006020 chronic inflammation Effects 0.000 title claims abstract description 8
- 239000003862 glucocorticoid Substances 0.000 claims abstract description 20
- 239000011368 organic material Substances 0.000 claims abstract description 19
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims description 38
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims description 38
- 239000012071 phase Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 229920001610 polycaprolactone Polymers 0.000 claims description 16
- 239000004632 polycaprolactone Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 108010010803 Gelatin Proteins 0.000 claims description 14
- 229920000159 gelatin Polymers 0.000 claims description 14
- 239000008273 gelatin Substances 0.000 claims description 14
- 229940014259 gelatin Drugs 0.000 claims description 14
- 235000019322 gelatine Nutrition 0.000 claims description 14
- 235000011852 gelatine desserts Nutrition 0.000 claims description 14
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 13
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 230000010102 embolization Effects 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 11
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 10
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 10
- -1 polysiloxane Polymers 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 229920001661 Chitosan Polymers 0.000 claims description 9
- 229960002537 betamethasone Drugs 0.000 claims description 9
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 9
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 9
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 9
- 229960003957 dexamethasone Drugs 0.000 claims description 8
- 230000003073 embolic effect Effects 0.000 claims description 8
- 238000004945 emulsification Methods 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 238000009210 therapy by ultrasound Methods 0.000 claims description 7
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 7
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 6
- 239000007764 o/w emulsion Substances 0.000 claims description 6
- 239000007762 w/o emulsion Substances 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 5
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 claims description 5
- 229920000954 Polyglycolide Polymers 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 229940057995 liquid paraffin Drugs 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 229920002401 polyacrylamide Polymers 0.000 claims description 5
- 239000004633 polyglycolic acid Substances 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 229960004063 propylene glycol Drugs 0.000 claims description 5
- 229940026235 propylene glycol monolaurate Drugs 0.000 claims description 5
- 239000001593 sorbitan monooleate Substances 0.000 claims description 5
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 5
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- VOBDXTSTTMAKHK-VHDCPBDGSA-N 3870-07-3 Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O VOBDXTSTTMAKHK-VHDCPBDGSA-N 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 108010022355 Fibroins Proteins 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 229920000375 Poly(ethylene glycol)-block-poly(ε−caprolactone) methyl ether Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- MKRNVBXERAPZOP-UHFFFAOYSA-N Starch acetate Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OC(C)=O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 MKRNVBXERAPZOP-UHFFFAOYSA-N 0.000 claims description 3
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 3
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229920003232 aliphatic polyester Polymers 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 229960001102 betamethasone dipropionate Drugs 0.000 claims description 3
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims description 3
- 229940045110 chitosan Drugs 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229960005188 collagen Drugs 0.000 claims description 3
- 229960003657 dexamethasone acetate Drugs 0.000 claims description 3
- 150000002009 diols Chemical class 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000012074 organic phase Substances 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 229940117828 polylactic acid-polyglycolic acid copolymer Drugs 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 30
- 229940079593 drug Drugs 0.000 abstract description 29
- 208000032843 Hemorrhage Diseases 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000000740 bleeding effect Effects 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 abstract description 3
- 239000002245 particle Substances 0.000 abstract description 3
- 206010006451 bronchitis Diseases 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000001186 cumulative effect Effects 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 10
- 238000005538 encapsulation Methods 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000011068 loading method Methods 0.000 description 8
- 239000002699 waste material Substances 0.000 description 8
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 238000009736 wetting Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 2
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000005119 Necrotizing Pneumonia Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/43—Hormones, e.g. dexamethasone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a sustained-release embolism microsphere for treating bronchiectasis hemoptysis caused by chronic inflammation, which has the particle size of 10-1000 mu m, is made of degradable or non-degradable organic material and is loaded with glucocorticoid. The invention can slowly release glucocorticoid while stopping bleeding by embolism, relieve and inhibit local inflammation, treat the change of lung structure caused by bronchitis and effectively avoid the relapse of hemoptysis. The slow release of the glucocorticoid in the invention can greatly improve the drug concentration of the focus part, relatively reduce the concentration of the drug in the circulatory system and reduce the side effect of the drug.
Description
Technical Field
The invention belongs to the technical field of interventional medical treatment, and particularly relates to a sustained-release embolism microsphere for treating bronchiectasis hemoptysis caused by chronic inflammation.
Background
Hemoptysis is a bleeding of the respiratory system, mainly caused by diseases of the trachea, bronchi and lung tissues. Among the most common causes of hemoptysis are infectious lung diseases, a class of which includes tuberculosis (40%), bronchiectasis (30%), necrotizing pneumonia (10%), lung abscesses (5%) and fungal infections (5%). Whereas lung cancer and arteriovenous malformations account for only 10% of all cases.
Bronchiectasis is chronic airway inflammation and irreversible dilation and deformation of the bronchial wall caused by various reasons. The factors such as infection, obstruction and the like cause the airway of a patient with bronchiectasis to have chronic inflammatory reaction, so that the epithelial cells of the bronchial mucosa are damaged, fall-off and necrosis occur, the wall of a single or multiple bronchial tubes of the patient is damaged, and then hemoptysis and even acute hemoptysis occur. The Bronchus Artery Embolization (BAE) has the advantages of minimal invasion, safety, rapid hemostatic effect and the like, and has become a preferred method for clinically treating hemoptysis caused by bronchiectasis.
Disclosure of Invention
The invention aims to provide a sustained-release embolism microsphere for treating bronchiectasis hemoptysis caused by chronic inflammation.
The technical scheme of the invention is as follows:
a sustained release embolism microsphere for treating bronchiectasis hemoptysis caused by chronic inflammation is prepared from degradable or non-degradable organic material loaded with glucocorticoid
The organic material is chitin, Chitosan (Chitosan), carboxymethyl Chitosan, sodium alginate, gelatin, collagen, Hyaluronic Acid (HA), polypeptide, silk fibroin, carboxymethyl starch, starch acetate, Polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), polylactic acid-polyglycolic acid copolymer (PLGA), polycaprolactone triol, polycaprolactone diol, poly (ethylene glycol) -block-poly (epsilon-caprolactone) methyl ether, polyvinyl alcohol (PVA), polyethylene terephthalate, Polyacrylamide (PAM), polyacrylate, polyhydroxyethyl methacrylate, aromatic polyester, polysiloxane, polyurethane, polyethylene oxide, linear aliphatic polyester, polyamino acid or polyvinylpyrrolidone (PVP).
In a preferred embodiment of the present invention, the glucocorticoid is at least one of clinically useful derivatives including dexamethasone, betamethasone, triamcinolone acetonide and dexamethasone, betamethasone and triamcinolone acetonide.
Further preferably, the glucocorticoid comprises at least one of dexamethasone, betamethasone, triamcinolone acetonide, dexamethasone acetate, dexamethasone sodium phosphate, betamethasone dipropionate and triamcinolone acetonide acetate.
In a preferred embodiment of the invention, the particle size is from 10 to 1000. mu.m.
In a preferred embodiment of the present invention, the organic material is water-soluble, and the preparation method thereof comprises:
(1) preparing the glucocorticoid into an aqueous solution, and mixing the aqueous solution with the organic material to prepare a water phase;
(2) adding a surfactant into the liquid paraffin, and uniformly stirring to prepare an oil phase;
(3) adding the water phase into the oil phase, fully mixing, and carrying out emulsification or crosslinking reaction;
(4) and (4) centrifuging, washing and vacuum freeze-drying the material obtained in the step (3) to obtain the sustained-release embolism microsphere.
Further preferably, the surfactant is at least one of sorbitan monooleate, propylene glycol monolaurate and propylene glycol fatty acid ester.
Still further preferably, the sorbitan monooleate is Span-80 or Arlacel-80, the propylene glycol monolaurate is Atlas G-917 or Atlas G-3851, and the propylene glycol fatty acid ester is Emcol PL-50.
In a preferred embodiment of the present invention, the organic material is insoluble in water and is prepared by a method comprising:
(1) preparing the glucocorticoid into an aqueous solution;
(2) adding the aqueous solution into an organic phase containing the organic material, and performing vortex emulsification to form a water-in-oil emulsion;
(3) adding the water-in-oil emulsion into a water-soluble dispersant, and further emulsifying to form a water-in-oil-in-water emulsion;
(4) and (3) placing the water-in-oil-in-water emulsion in ice bath for ultrasonic treatment, stirring for 10-15h, and then sequentially centrifuging, washing and vacuum freeze-drying to obtain the slow-release embolism microsphere.
The invention has the beneficial effects that:
1. the invention can slowly release glucocorticoid while stopping bleeding by embolism, relieve and inhibit local inflammation, treat the change of lung structure caused by bronchitis and effectively avoid the relapse of hemoptysis.
2. The slow release of the glucocorticoid in the invention can greatly improve the drug concentration of the focus part, relatively reduce the concentration of the drug in the circulatory system and reduce the side effect of the drug.
3. The combination of the medicine and the microspheres in the invention is convenient for doctors to operate and brings convenience to patients.
Drawings
FIG. 1 is a scanning electron microscope image of dexamethasone sodium phosphate gelatin sustained-release embolization microspheres prepared in example 2 of the present invention.
FIG. 2 is a scanning electron microscope image of dexamethasone sodium phosphate polyvinyl alcohol sustained-release embolization microspheres prepared in example 3 of the present invention.
FIG. 3 is a scanning electron microscope image of dexamethasone sodium phosphate polycaprolactone sustained-release embolization microspheres prepared in example 4 of the present invention.
FIG. 4 is a scanning electron microscope image of dexamethasone sodium phosphate PLGA sustained-release embolization microspheres prepared in example 5 of the present invention.
FIG. 5 is a diagram of the results of in vitro drug release experiments of dexamethasone sodium phosphate gelatin sustained-release embolization microspheres prepared in example 2 of the invention.
FIG. 6 is a diagram showing the results of in vitro drug release experiments of dexamethasone sodium phosphate-polyvinyl alcohol sustained release embolization microspheres prepared in example 3 of the present invention.
FIG. 7 is a diagram showing the results of in vitro drug release experiments of dexamethasone sodium phosphate polycaprolactone sustained-release embolization microspheres prepared in example 4 of the present invention.
FIG. 8 is a graph showing the results of in vitro drug release experiments of dexamethasone sodium phosphate PLGA sustained release embolization microspheres prepared in example 5 of the present invention.
Detailed Description
The technical solution of the present invention will be further illustrated and described below with reference to the accompanying drawings by means of specific embodiments.
Example 1
A sustained-release embolism microsphere for treating bronchiectasis hemoptysis caused by chronic inflammation has particle diameter of 10-1000 μm. The material is degradable or non-degradable organic material, which is loaded with glucocorticoid, wherein
The organic material is chitin, Chitosan (Chitosan), carboxymethyl Chitosan, sodium alginate, gelatin, collagen, Hyaluronic Acid (HA), polypeptide, silk fibroin, carboxymethyl starch, starch acetate, Polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), polylactic acid-polyglycolic acid copolymer (PLGA), polycaprolactone triol, polycaprolactone diol, poly (ethylene glycol) -block-poly (epsilon-caprolactone) methyl ether, polyvinyl alcohol (PVA), polyethylene terephthalate, Polyacrylamide (PAM), polyacrylate, polyhydroxyethyl methacrylate, aromatic polyester, polysiloxane, polyurethane, polyethylene oxide, linear aliphatic polyester, polyamino acid or polyvinylpyrrolidone (PVP).
The glucocorticoid is at least one of dexamethasone, betamethasone, triamcinolone acetonide and derivatives of dexamethasone, betamethasone and triamcinolone acetonide which can be used clinically. Further preferably, the glucocorticoid comprises at least one of dexamethasone, betamethasone, triamcinolone acetonide, dexamethasone acetate, dexamethasone sodium phosphate, betamethasone dipropionate and triamcinolone acetonide acetate.
When the organic material is water-soluble, the preparation method thereof comprises:
(1) preparing the glucocorticoid into an aqueous solution, and mixing the aqueous solution with the organic material to prepare a water phase;
(2) adding a surfactant into the liquid paraffin, and uniformly stirring to prepare an oil phase, wherein the surfactant is at least one of sorbitan monooleate (Span-80/Arlacel-80), propylene glycol monolaurate (Atlas G-917/Atlas G-3851) and propylene glycol fatty acid ester (Emcol PL-50);
(3) adding the water phase into the oil phase, fully mixing, and carrying out emulsification or crosslinking reaction;
(4) and (4) centrifuging, washing and vacuum freeze-drying the material obtained in the step (3) to obtain the sustained-release embolism microsphere.
When the organic material is not soluble in water, the preparation method thereof comprises:
(1) preparing the glucocorticoid into an aqueous solution;
(2) adding the aqueous solution into an organic phase containing the organic material, and performing vortex emulsification to form a water-in-oil emulsion;
(3) adding the water-in-oil emulsion into a water-soluble dispersant, and further emulsifying to form a water-in-oil-in-water emulsion;
(4) and (3) placing the water-in-oil-in-water emulsion in ice bath for ultrasonic treatment, stirring for 10-15h, and then sequentially centrifuging, washing and vacuum freeze-drying to obtain the slow-release embolism microsphere.
Example 2 preparation of dexamethasone sodium phosphate gelatin sustained release embolization microspheres
(1) Preparation of microspheres
Completely dissolving the prepared chitosan solution with the concentration of 20% in a water bath at 50-60 ℃, adding the dexamethasone sodium phosphate solution, and fully and uniformly mixing to prepare a water phase. Adding a proper amount of Span-80 into liquid paraffin as an oil phase, placing the oil phase into a three-necked bottle in a constant-temperature water bath at 50 ℃, slowly and dropwise adding the water phase into the oil phase for emulsification under the condition that the stirring speed is 200-1 r.min < -1 >, and the water-oil ratio is 1: 4-1: 8. When the emulsion drops are made into spheres with proper size through microscopic examination, namely emulsifying to form stable W/O type emulsion, rapidly cooling to below 5 ℃, respectively adding formaldehyde or 50% glutaraldehyde for curing for 1-2h, centrifuging the obtained product at 3000r/min, washing with isopropanol and acetone for 3 times, filtering, and freeze-drying in vacuum to finally obtain the dexamethasone sodium phosphate gelatin sustained-release embolism microsphere shown in figure 1.
(2) Encapsulation efficiency and drug load measurements
Chromatographic conditions are as follows: c18Analytical column 4.6mm × 2.5mm, 5 μm;
mobile phase triethylamine solution-methanol-acetonitrile 55: 40: 5
Wherein the triethylamine solution: adding water into 7.5mL of triethylamine to dilute to 1000mL, and adjusting with phosphoric acid
The pH value is 3.0.
An ultraviolet detector with a detection wavelength of 242nm
In the preparation process of the microspheres, collecting the waste liquid in each step, detecting the content of dexamethasone sodium phosphate in the waste liquid by using a high performance liquid chromatography, and calculating the encapsulation rate and the drug loading rate according to the following formula:
(3) in vitro drug release assay
Weighing a proper amount of the dexamethasone sodium phosphate gelatin sustained-release embolism microsphere, adding PBS (20mmol/L, pH7.4) for wetting, then placing into a 50mL conical flask, adding 30mL of PBS containing 1 per mill of sodium azide, then placing the conical flask into a constant-temperature water bath shaking table, setting the temperature at 37 ℃, and rotating at 80 rpm. Samples were taken at 1, 2, 3, 5, 7, 14, 21, 28d after placement, 5mL each time, supplemented with 5mL PBS. Centrifuging the sample, taking the supernatant to detect the content of dexamethasone sodium phosphate, and calculating the cumulative release according to the following formula:
as a result: the average entrapment rate of the dexamethasone sodium phosphate gelatin sustained-release embolism microsphere prepared by the embodiment reaches 83.61%, and the average drug loading rate is 7.82%; according to the in vitro release law, as can be seen from the cumulative release curve shown in fig. 5, the release rate is faster in week 1, and the release rate gradually slows down from week 2, with the curve also tending to be slightly gentle. The cumulative release of drug from the microspheres exceeded 40% over a 4 week period. Can meet the characteristics of taking intervention embolism as the main part and taking drug therapy as the auxiliary part in the clinical treatment of bronchiectasis hemoptysis.
Example 3 preparation of dexamethasone sodium phosphate polyvinyl alcohol sustained release embolization microspheres
(1) Preparation of microspheres
Under the condition of stirring, adding 2g of surfactant Span-80 into 40mL of liquid paraffin to form a continuous phase oil phase; after stirring uniformly, 10mL of a mixed solution of polyvinyl alcohol and dexamethasone sodium phosphate is added into the continuous oil phase, after full mixing, 1g of Sodium Trimetaphosphate (STMP) is added as a cross-linking agent, and 1mL of NaOH is immediately added as a catalyst. The rotation speed is set to be 400rpm, the temperature is set to be 50 ℃, and the crosslinking reaction time is set to be 16 h. After the crosslinking reaction was completed, the mixture was allowed to stand for 30 min. Adding a small amount of anhydrous ethanol, centrifuging in a centrifuge, taking out supernatant, repeatedly washing precipitate with anhydrous ethanol, isopropanol and pure water, and vacuum freeze drying to obtain dexamethasone sodium phosphate polyvinyl alcohol sustained-release embolism microsphere shown in figure 2.
(2) Encapsulation efficiency and drug load measurements
Chromatographic conditions are as follows: c18Analytical column 4.6mm × 2.5mm, 5 μm;
mobile phase triethylamine solution-methanol-acetonitrile 55: 40: 5
Wherein the triethylamine solution: adding water into 7.5mL of triethylamine to dilute to 1000mL, and adjusting with phosphoric acid
The pH value is 3.0.
An ultraviolet detector with a detection wavelength of 242nm
In the preparation process of the microspheres, collecting the waste liquid in each step, detecting the content of dexamethasone sodium phosphate in the waste liquid by using a high performance liquid chromatography, and calculating the encapsulation rate and the drug loading rate according to the following formula:
(3) in vitro drug release assay
Weighing a proper amount of the dexamethasone sodium phosphate polyvinyl alcohol sustained-release embolism microsphere, adding PBS (20mmol/L, pH7.4) for wetting, then placing into a 50mL conical flask, adding 30mL of PBS containing 1 per mill of sodium azide, then placing the conical flask into a constant-temperature water bath shaking table, setting the temperature at 37 ℃, and rotating at 80 rpm. Samples were taken at 1, 2, 3, 5, 7, 14, 21, 28d after placement, 5mL each time, supplemented with 5mL PBS. Centrifuging the sample, taking the supernatant to detect the content of dexamethasone sodium phosphate, and calculating the cumulative release according to the following formula:
as a result: the average encapsulation rate of the dexamethasone sodium phosphate gelatin sustained-release embolism microsphere prepared by the embodiment reaches 85.2%, and the average drug-loading rate is 8.14%; according to the in vitro release law, as can be seen from the cumulative release curve shown in fig. 6, the release rate is faster in week 1, and the release rate gradually slows down from week 2, with the curve also tending to be slightly gentle. The cumulative release of drug from the microspheres exceeded 40% over a 4 week period. Can meet the characteristics of taking intervention embolism as the main part and taking drug therapy as the auxiliary part in the clinical treatment of bronchiectasis hemoptysis.
Example 4 preparation of dexamethasone sodium phosphate polycaprolactone sustained-release embolism microsphere
(1) Preparation of microspheres
Dissolving polycaprolactone in dichloromethane under a closed condition, adding Span-80, and uniformly mixing to obtain an oil phase; adding dexamethasone sodium phosphate solution as internal water phase into the oil phase, and performing ultrasonic treatment for 3min to form primary emulsion; adding PVA water solution into the primary emulsion, and performing ultrasonic treatment again to form W/O/W type composite emulsion; stirring the obtained composite emulsion for 3 hours at room temperature under an open condition, and volatilizing dichloromethane; washing with distilled water for 2 times, and lyophilizing to obtain dexamethasone sodium phosphate polycaprolactone sustained-release embolism microsphere shown in figure 3.
(2) Encapsulation efficiency and drug load measurements
Chromatographic conditions are as follows: c18Analytical column 4.6mm × 2.5mm, 5 μm;
mobile phase triethylamine solution-methanol-acetonitrile 55: 40: 5
Wherein the triethylamine solution: adding water into 7.5mL of triethylamine to dilute to 1000mL, and adjusting with phosphoric acid
The pH value is 3.0.
An ultraviolet detector with a detection wavelength of 242nm
In the preparation process of the microspheres, collecting the waste liquid in each step, detecting the content of dexamethasone sodium phosphate in the waste liquid by using a high performance liquid chromatography, and calculating the encapsulation rate and the drug loading rate according to the following formula:
(3) in vitro drug release assay
Weighing a proper amount of the dexamethasone sodium phosphate gelatin sustained-release embolism microsphere, adding PBS (20mmol/L, pH7.4) for wetting, then placing into a 50mL conical flask, adding 30mL of PBS containing 1 per mill of sodium azide, then placing the conical flask into a constant-temperature water bath shaking table, setting the temperature at 37 ℃, and rotating at 80 rpm. Samples were taken at 1, 2, 3, 5, 7, 14, 21, 28d after placement, 5mL each time, supplemented with 5mL PBS. Centrifuging the sample, taking the supernatant to detect the content of dexamethasone sodium phosphate, and calculating the cumulative release according to the following formula:
as a result: the average entrapment rate of the dexamethasone sodium phosphate gelatin sustained-release embolism microsphere prepared by the embodiment reaches 76.23%, and the average drug loading rate is 6.84%; according to the in vitro release law, as can be seen from the cumulative release curve shown in fig. 7, the release rate is faster in week 1, and the release rate gradually slows down from week 2, with the curve also tending to be slightly gentle. The cumulative release of drug from the microspheres exceeded 40% over a 4 week period. Can meet the characteristics of taking intervention embolism as the main part and taking drug therapy as the auxiliary part in the clinical treatment of bronchiectasis hemoptysis.
Example 5 preparation of dexamethasone sodium phosphate PLGA sustained Release embolic microspheres
(1) Preparation of microspheres
Under a closed condition, dissolving PLGA in dichloromethane, adding Span-80, and uniformly mixing to obtain an oil phase; adding dexamethasone sodium phosphate solution as internal water phase into the oil phase, and performing ultrasonic treatment for 3min to form primary emulsion; adding PVA water solution into the primary emulsion, and performing ultrasonic treatment again to form W/O/W type composite emulsion; stirring the obtained composite emulsion for 3 hours at room temperature under an open condition, and volatilizing dichloromethane; washing with distilled water for 2 times, and lyophilizing to obtain dexamethasone sodium phosphate PLGA sustained release embolism microsphere shown in figure 4.
(2) Encapsulation efficiency and drug load measurements
Chromatographic conditions are as follows: c18Analytical column 4.6mm × 2.5mm, 5 μm;
mobile phase triethylamine solution-methanol-acetonitrile 55: 40: 5
Wherein the triethylamine solution: adding water into 7.5mL of triethylamine to dilute to 1000mL, and adjusting with phosphoric acid
The pH value is 3.0.
An ultraviolet detector with a detection wavelength of 242nm
In the preparation process of the microspheres, collecting the waste liquid in each step, detecting the content of dexamethasone sodium phosphate in the waste liquid by using a high performance liquid chromatography, and calculating the encapsulation rate and the drug loading rate according to the following formula:
(3) in vitro drug release assay
Weighing a proper amount of the dexamethasone sodium phosphate gelatin sustained-release embolism microsphere, adding PBS (20mmol/L, pH7.4) for wetting, then placing into a 50mL conical flask, adding 30mL of PBS containing 1 per mill of sodium azide, then placing the conical flask into a constant-temperature water bath shaking table, setting the temperature at 37 ℃, and rotating at 80 rpm. Samples were taken at 1, 2, 3, 5, 7, 14, 21, 28d after placement, 5mL each time, supplemented with 5mL PBS. Centrifuging the sample, taking the supernatant to detect the content of dexamethasone sodium phosphate, and calculating the cumulative release according to the following formula:
as a result: the average entrapment rate of the dexamethasone sodium phosphate gelatin sustained-release embolism microsphere prepared by the embodiment reaches 78.22%, and the average drug loading rate is 6.37%; according to the in vitro release law, as can be seen from the cumulative release curve shown in fig. 8, the release rate is faster in week 1, and the release rate gradually slows down from week 2, with the curve also tending to be slightly gentle. The cumulative release of drug from the microspheres exceeded 40% over a 4 week period. Can meet the characteristics of taking intervention embolism as the main part and taking drug therapy as the auxiliary part in the clinical treatment of bronchiectasis hemoptysis.
The above description is only a preferred embodiment of the present invention, and therefore should not be taken as limiting the scope of the invention, which is defined by the appended claims.
Claims (8)
1. A sustained release embolization microsphere for treating bronchiectasis hemoptysis caused by chronic inflammation, which is characterized in that: the material is degradable or non-degradable organic material, which is loaded with glucocorticoid, wherein the organic material is chitin, chitosan, carboxymethyl chitosan, sodium alginate, gelatin, collagen, hyaluronic acid, polypeptide, silk fibroin, carboxymethyl starch, starch acetate, polycaprolactone, polylactic acid, polyglycolic acid, polylactic acid-polyglycolic acid copolymer, polycaprolactone triol, polycaprolactone diol, poly (ethylene glycol) -block-poly (epsilon-caprolactone) methyl ether, polyvinyl alcohol, polyethylene glycol terephthalate, polyacrylamide, polyacrylate, polyhydroxyethyl methacrylate, aromatic polyester, polysiloxane, polyurethane, polyethylene oxide, linear aliphatic polyester, polyamino acid or polyvinylpyrrolidone.
2. The sustained-release embolic microsphere of claim 1, wherein: the glucocorticoid is at least one of dexamethasone, betamethasone, triamcinolone acetonide and derivatives of dexamethasone, betamethasone and triamcinolone acetonide which can be used clinically.
3. The sustained-release embolic microsphere of claim 2, wherein: the glucocorticoid comprises at least one of dexamethasone, betamethasone, triamcinolone acetonide, dexamethasone acetate, dexamethasone sodium phosphate, betamethasone dipropionate and triamcinolone acetonide acetate.
4. The sustained-release embolic microsphere of claim 1, wherein: the grain diameter is 10-1000 μm.
5. A slow release embolic microsphere as claimed in any one of claims 1 to 4, wherein: the organic material is water-soluble, and the preparation method comprises the following steps:
(1) preparing the glucocorticoid into an aqueous solution, and mixing the aqueous solution with the organic material to prepare a water phase;
(2) adding a surfactant into the liquid paraffin, and uniformly stirring to prepare an oil phase;
(3) adding the water phase into the oil phase, fully mixing, and carrying out emulsification or crosslinking reaction;
(4) and (4) centrifuging, washing and vacuum freeze-drying the material obtained in the step (3) to obtain the sustained-release embolism microsphere.
6. The sustained-release embolic microsphere of claim 5, wherein: the surfactant is at least one of sorbitan monooleate, propylene glycol monolaurate and propylene glycol fatty acid ester.
7. The sustained-release embolic microsphere of claim 6, wherein: the sorbitan monooleate is Span-80 or Arlacel-80, the propylene glycol monolaurate is Atlas G-917 or Atlas G-3851, and the propylene glycol fatty acid ester is Emcol PL-50.
8. A slow release embolic microsphere as claimed in any one of claims 1 to 4, wherein: the organic material is insoluble in water and is prepared by a method comprising:
(1) preparing the glucocorticoid into an aqueous solution;
(2) adding the aqueous solution into an organic phase containing the organic material, and performing vortex emulsification to form a water-in-oil emulsion;
(3) adding the water-in-oil emulsion into a water-soluble dispersant, and further emulsifying to form a water-in-oil-in-water emulsion;
(4) and (3) placing the water-in-oil-in-water emulsion in ice bath for ultrasonic treatment, stirring for 10-15h, and then sequentially centrifuging, washing and vacuum freeze-drying to obtain the slow-release embolism microsphere.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911216938.6A CN112972753A (en) | 2019-12-02 | 2019-12-02 | Sustained-release embolism microsphere for treating bronchiectasis hemoptysis caused by chronic inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911216938.6A CN112972753A (en) | 2019-12-02 | 2019-12-02 | Sustained-release embolism microsphere for treating bronchiectasis hemoptysis caused by chronic inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112972753A true CN112972753A (en) | 2021-06-18 |
Family
ID=76331354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911216938.6A Pending CN112972753A (en) | 2019-12-02 | 2019-12-02 | Sustained-release embolism microsphere for treating bronchiectasis hemoptysis caused by chronic inflammation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112972753A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115089593A (en) * | 2022-05-20 | 2022-09-23 | 广东南国药业有限公司 | Dexamethasone preparation and preparation method thereof |
| CN116803382A (en) * | 2023-08-21 | 2023-09-26 | 江苏长泰药业股份有限公司 | Triamcinolone acetonide sustained release microsphere, preparation method and triamcinolone acetonide sustained release preparation |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030211165A1 (en) * | 2000-03-24 | 2003-11-13 | Jean-Marie Vogel | Microspheres for active embolization |
| CN1470240A (en) * | 2003-06-25 | 2004-01-28 | 暨南大学 | A controllable release system of glucocorticoid and its preparation and application |
| CN1939316A (en) * | 2005-09-28 | 2007-04-04 | 中国人民解放军军事医学科学院毒物药物研究所 | Microsphere containing adriamycin, its usage and preparation |
| EP1810698A1 (en) * | 2006-01-24 | 2007-07-25 | Biocompatibles UK Limited | Process for producing radiopaque embolic microspheres |
| WO2007090897A1 (en) * | 2006-02-10 | 2007-08-16 | Biocompatibles Uk Limited | Loading of hydrophobic drugs into hydrophilic polymer delivery systems |
| CN101530618A (en) * | 2009-04-13 | 2009-09-16 | 莫始平 | Pharmaceutical composition for the treatment of chronic obstructive pulmonary disease and bronchial asthma |
| CN101912366A (en) * | 2010-08-03 | 2010-12-15 | 中国人民解放军第三〇九医院 | A kind of degradable gel microsphere inserted into bronchi and its application |
| CA2732488A1 (en) * | 2010-01-27 | 2011-07-27 | Biosphere Medical, Inc. | Microspheres useful for therapeutic vascular embolization |
| CN102309458A (en) * | 2010-07-09 | 2012-01-11 | 北京圣医耀科技发展有限责任公司 | Sodium alginate crosslinking moxifloxacin sustained-release microspheres and preparation method and application thereof, and vascular target suppository containing microsphere |
| CN104324032A (en) * | 2011-03-07 | 2015-02-04 | 中国人民解放军第三〇九医院 | Triple compound microsphere vascular targeted embolization sustained-release preparation containing antituberculous drug as well as preparation method and application of preparation |
| WO2017101022A1 (en) * | 2015-12-15 | 2017-06-22 | 江阴市本特塞缪森生命科学研究院有限公司 | Modified medical scaffold material |
| CN108114310A (en) * | 2017-12-22 | 2018-06-05 | 张海军 | A kind of degradable high drug load embolism microball and preparation method thereof |
| CN110237052A (en) * | 2019-07-11 | 2019-09-17 | 苏州大学 | A kind of triamcinolone acetonide acetate sustained-release microspheres and preparation method thereof |
-
2019
- 2019-12-02 CN CN201911216938.6A patent/CN112972753A/en active Pending
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030211165A1 (en) * | 2000-03-24 | 2003-11-13 | Jean-Marie Vogel | Microspheres for active embolization |
| CN1470240A (en) * | 2003-06-25 | 2004-01-28 | 暨南大学 | A controllable release system of glucocorticoid and its preparation and application |
| CN1939316A (en) * | 2005-09-28 | 2007-04-04 | 中国人民解放军军事医学科学院毒物药物研究所 | Microsphere containing adriamycin, its usage and preparation |
| EP1810698A1 (en) * | 2006-01-24 | 2007-07-25 | Biocompatibles UK Limited | Process for producing radiopaque embolic microspheres |
| WO2007090897A1 (en) * | 2006-02-10 | 2007-08-16 | Biocompatibles Uk Limited | Loading of hydrophobic drugs into hydrophilic polymer delivery systems |
| CN101530618A (en) * | 2009-04-13 | 2009-09-16 | 莫始平 | Pharmaceutical composition for the treatment of chronic obstructive pulmonary disease and bronchial asthma |
| CA2732488A1 (en) * | 2010-01-27 | 2011-07-27 | Biosphere Medical, Inc. | Microspheres useful for therapeutic vascular embolization |
| CN102309458A (en) * | 2010-07-09 | 2012-01-11 | 北京圣医耀科技发展有限责任公司 | Sodium alginate crosslinking moxifloxacin sustained-release microspheres and preparation method and application thereof, and vascular target suppository containing microsphere |
| CN101912366A (en) * | 2010-08-03 | 2010-12-15 | 中国人民解放军第三〇九医院 | A kind of degradable gel microsphere inserted into bronchi and its application |
| CN104324032A (en) * | 2011-03-07 | 2015-02-04 | 中国人民解放军第三〇九医院 | Triple compound microsphere vascular targeted embolization sustained-release preparation containing antituberculous drug as well as preparation method and application of preparation |
| WO2017101022A1 (en) * | 2015-12-15 | 2017-06-22 | 江阴市本特塞缪森生命科学研究院有限公司 | Modified medical scaffold material |
| CN108114310A (en) * | 2017-12-22 | 2018-06-05 | 张海军 | A kind of degradable high drug load embolism microball and preparation method thereof |
| CN110237052A (en) * | 2019-07-11 | 2019-09-17 | 苏州大学 | A kind of triamcinolone acetonide acetate sustained-release microspheres and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 凌春生: "《实用药剂学》", 30 September 2008, 中国医药科技出版社 * |
| 石拯拯等: "带药微球缓释栓塞制剂的研究现状", 《中华临床医师杂志(电子版)》 * |
| 谈志远等: "顺铂微球支气管动脉栓塞治疗肺癌伴大咯血4例", 《医学理论与实践》 * |
| 钱军民等: "聚合物微球的制备及在药物缓释/控释中的应用", 《精细石油化工进展》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115089593A (en) * | 2022-05-20 | 2022-09-23 | 广东南国药业有限公司 | Dexamethasone preparation and preparation method thereof |
| CN116803382A (en) * | 2023-08-21 | 2023-09-26 | 江苏长泰药业股份有限公司 | Triamcinolone acetonide sustained release microsphere, preparation method and triamcinolone acetonide sustained release preparation |
| CN116803382B (en) * | 2023-08-21 | 2023-12-01 | 江苏长泰药业股份有限公司 | Triamcinolone acetonide sustained release microsphere, preparation method and triamcinolone acetonide sustained release preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Use of ginsenoside Rg3-loaded electrospun PLGA fibrous membranes as wound cover induces healing and inhibits hypertrophic scar formation of the skin | |
| US10624854B2 (en) | Method for preparing degradable drug-loaded microsphere for embolization, and product obtained therefrom | |
| JP5345141B2 (en) | Microsphere with core / shell structure | |
| WO2017133419A1 (en) | Drug-loaded microsphere and preparation method and use thereof | |
| CN113117135A (en) | Anti-tumor vascular drug sustained-release embolization microsphere for interventional therapy of malignant tumor | |
| CN104288833B (en) | A kind of containing can the composite reactive bone cement and preparation method thereof of slow release drug-loading nanoparticles | |
| CN112972753A (en) | Sustained-release embolism microsphere for treating bronchiectasis hemoptysis caused by chronic inflammation | |
| CN110237052A (en) | A kind of triamcinolone acetonide acetate sustained-release microspheres and preparation method thereof | |
| Graves et al. | Effect of different ratios of high and low molecular weight PLGA blend on the characteristics of pentamidine microcapsules | |
| CN101721375B (en) | Insulin sustained-release microsphere composition and preparation method thereof | |
| CN118477048B (en) | Bulleprazole sustained-release microsphere and preparation method thereof | |
| CN112791228A (en) | Slow-release embolism microsphere for pulmonary tuberculosis hemoptysis | |
| CN106474070B (en) | Microsphere capable of overcoming stagnation period and releasing hydrophobic drugs at constant speed and preparation method thereof | |
| Mei et al. | Formulation and in vitro characterization of rifampicin-loaded porous poly (ε-caprolactone) microspheres for sustained skeletal delivery | |
| CN108403663A (en) | GO-PEG gel micro-balls with nucleocapsid and its preparation method and application | |
| CN103990185A (en) | Carrageenan and gelatin microsphere embolization agent and preparation method thereof | |
| KR20160019022A (en) | A method for producing micro particle for biodegradable filler | |
| CN105030699B (en) | The complex microsphere and preparation method and application of release growth factor and antibiotic in order | |
| Zhu et al. | A biodegradable long-term contraceptive implant with steady levonorgestrel release based on PLGA microspheres embedded in PCL-coated implant | |
| WO2006123361A2 (en) | Microspheres containing goserelin or a pharmaceutically acceptable salt thereof | |
| CN118806724A (en) | Drug delivery carrier for inhibiting glycogen release and treating large liposarcoma and preparation method thereof | |
| CN101721376B (en) | Calcitonin sustained-release microsphere composition and preparation method thereof | |
| CN111803450B (en) | Nano-reinforced degradable polymer microsphere and preparation method and application thereof | |
| JP5808413B2 (en) | Method for removing residual organic solvent from fine particles | |
| CN101822636A (en) | Slowly released and controlled-drug delivery system of injectable estriol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210618 |